RNA- and DNA-Based Assays for Predicting Paclitaxel Resistance in Triple Negative Breast Cancer
Search text
Xiaosong Wang
About 3 results
(0.03 seconds)
Researchers at University of Pittsburgh have discovered a non-traditional molecular event underlying molecular pathobiology of more aggressive and metastatic breast cancer. To date, this fusion remains the most frequently expressed tumor-specific fusion transcript reported in luminal breast tumors. · Using MEK inhibitors to prevent and treat breast cancer metastasis in a substantial population of breast cancer patients.
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Most importantly, these developments indicate that breast cancer cells expressing ectopic or endogenous forms of this ESR1 fusion are highly sensitivity to concomitant treatment with tamoxifen and dasatinib. Endocrine therapy is the most effective treatment option for estrogen-receptor (ER) positive breast cancer, but its efficacy is limited by both intrinsic and acquired endocrine resistance.
Through Pan-Cancer Analysis of Whole Genomes, it has been found that IGR burden is a pivotal contributor to increased T-inflamed signature in selected tumor entities such as breast cancer, ovarian cancer, uterine corpus endometrial cancer, and esophageal adenocarcinoma, and correlates with increased type-I immune response effectors, such as Macrophage M1 and CD8+ T cells. However, none of these is singly sufficient to discriminate all responders from non-responders, especially in TMB low cancer types. Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer.